邵凤，博士，研究员，中国药科大学药物代谢动力学专业博士，南澳大学临床研究中心博士后。2007-2014年在国内/外制药公司（先声药业、Novartis上海、苏州信达）从事创新药研发工作，2014年8月作为人才引进加入江苏省人民医院，临床研究主要研究者（PI），I期临床研究学术带头人。入选江苏省第四期“333高层次人才培养工程”，江苏省第十四期“六大人才高峰”高层次人才；2020年获第七届江苏医药科技奖“医药科技进步奖二等奖”；同时兼任“中国医药质量管理协会智能化药物临床研究专业委员会”副主任委员；江苏省药理学会临床药理专委会副主任委员，南京医科大学第一附属医院（江苏省人民医院）伦理委员会委员，十三五重大专项“创新药临床评价的同位素示踪技术平台”子项目负责人。
主要科研方向：1）创新药临床药理及药代动力学研究；2）pop-PK/PD，PBPK等模型的定量药理学研究；3）药物传递系统的研究
代表性科研项目：迄今作为PI/Co-PI完成I期临床项目50多项，代表性I期临床研究包括呋奎替尼、阿美替尼、恩沙替尼，盐酸凯普拉生（H008）等，已经获批上市，主持完成的关键注册临床研究（LY01008生物仿制药项目）支持了生物仿制药-贝伐珠单抗注射液在国内上市。
主要科研成果：以通讯作者或第一作者在Clin Ther，Cancer Chemother Pharmacol，Eur J Clin Pharmacol，Int J Biol Macromol，J Agric Food Chem，J Chromatogr B等高水平期刊上发表论文40余篇，技术方法同时被国内外同行借鉴和采用，总引次数>700。受邀参编《药剂学》（第四版，人民卫生出版社）；作为副主编，编撰《放射性核素示踪技术在新药临床评价中的应用》。另外，作为申请人目前已获包括“一种检测CYP2C19基因多态性的检测位点、引物组合物及其应用”在内的6项专利。
招生方向：临床药学（专业学位）硕士
Dr. Feng SHAO is professor of Nanjing Medical University School of Pharmacy and director in Department of Clinical Pharmacology/Phase I clinical trials Unit , the First Affiliated Hospital With Nanjing Medical University. Prior to joining the university or the hospital, Dr. Shao served as clinical pharmacologist or Director in pharmaceutical industry ( e.g. Simcere, Novartis, Innovent) nearly for seven years. Dr. Shao’s area of interest includes clinical pharmacology, PB/PK/PD modelling and simulation, and drug-drug interactions, and has published over 20 papers in recent three years in the field of pharmacology. She is elected as the vice chairman of Committee of Clinical Pharmacology of Jiangsu Province and Ethics committee member of Jiangsu Province Hospital recently.
联系方式：shaofengnj@163.com 或shaofeng@jsph.org.cn
近5年代表性论文：
1. Zhao Y, Xie L, Zhang H, Zhou S, Liu Y, Chen J, Wang L, Wang L, Zhuo L, Wang Y, Ou N, Shao F*. Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of SY-004, a Glucokinase Activator, in Healthy Chinese Adults: A Randomized, Phase Ia, Single-Ascending Dose Study. Clin Ther. 2022 Feb;44(2):269-281
2. Lu J, Wang L, Zhou S, Zhou C, Xie L, Chen J, Tang D, Tian X, Xie D, Ding J, Wang T, Yu Q, Ding J, Shao F*. A double-blind, randomized, placebo and positive-controlled study in healthy volunteers to evaluate pharmacokinetic and pharmacodynamic properties of multiple oral doses of cetagliptin. Br J Clin Pharmacol. 2021 Dec 29.
3. Zhu J, Zhao Y, Wang L, Zhou C, Zhou S, Chen T, Chen J, Zhang Z, Zhu Y, Ding S, Shao F*, Physiologically based pharmacokinetic/pharmacodynamic modeling to evaluate the absorption of midazolam rectal gel. Eur J Pharm Sci. 2021 Sep 11;167
4. Zhang S, Asghar S, Zhu C, Ye J, Lin L, Xu L, Hu Z, Chen Z, Shao F*, Xiao Y*. Multifunctional nanorods based on self-assembly of biomimetic apolipoprotein E peptide for the treatment of Alzheimer's disease. J Control Release. 2021 Jul 10;335:637-649.
5. Lu Wang#, Lian Guo#, Yixiang Wang, Renhua Guo, Zhaoqiang Xu, Zhengzhen Gao, Lijun Xie, Juan Chen, Ying Chen, Yun Liu, Hongwen Zhang, Lihua Bao, Wanhong Xu, Mingshe Zhu, 6, Feng Shao*, Yongqian Shu*,Metabolic disposition of [14C]-abivertinib, an epidermal growth factor receptor tyrosine kinase inhibitor: role of glutathione conjugation, Br J Clin Pharmacol. 2021 Mar;87(3):1475-1485
6. Sufeng Zhou, Wei Liu, Chen Zhou, Lijun Xie, Zhaoqiang Xu , Lu Wang, Yuqing Zhao, Juan Chen, Lieming Ding, Li Mao, Chen Zhang, Sijia Ding, Feng Shao* , Mass balance, metabolic disposition, and pharmacokinetics of [14C]Ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration,Cancer Chemother Pharmacol. (2020) 86:719–730
7. Tian C, Asghar S, Hu Z, Qiu Y, Zhang J, Shao F*, Xiao Y*, Understanding the cellular uptake and biodistribution of a dual- targeting carrier based on redox-sensitive hyaluronic acid-ss-curcumin micelles for treating brain glioma. Int J Biol Macromol. 2019 Sep 1;136:143-153
8. Zhang S, Asghar S, Yu F, Chen Z, Hu Z, Ping Q, Shao F*, Xiao Y*, .BSA Nanoparticles Modified with N-Acetylcysteine for Improving the Stability and Mucoadhesion of Curcumin in the Gastrointestinal Tract. J Agric Food Chem. 2019 Aug 21;67(33):9371-9381
9. Zhou S, Tao M, Wang Y, Wang L, Xie L, Chen J, Zhao Y, Liu Y, Zhang H, Ou N, Wang G, Shao F*, Aa J*. Effects of CYP3A4*1G and CYP3A5*3 polymorphisms on pharmacokinetics of tylerdipine hydrochloride in healthy Chinese subjects. Xenobiotica. 2019 Mar;49(3):375-380
10. Tao M, Zhou S, Wang Y, Wang L, Zhao Y, Xie L, Chen J, Liu Y, Zhang H, Ou N, Wang G, Shao F*, Aa J. Development and validation of two LC-MS/MS methods to assay urinary tylerdipine hydrochloride and its metabolites in healthy Chinese subjects. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Oct 1;1096:172-179.
